MeiraGTx: Positive PD Data Moves Needle Forward For Regulatory Meetings [Seeking Alpha]
MeiraGTx Holdings plc - Ordinary Shares (MGTX)
Company Research
Source: Seeking Alpha
Investing Group Leader Follow Play 13min Summary MeiraGTx Holdings plc's GAD gene therapy for Parkinson's Disease shows promising phase 1/2 results, with significant improvements in UPDRS Part 3 and PDQ-39 scores. The company plans to discuss phase 3 study designs with regulatory agencies in Q4 2024, potentially initiating late-stage studies in 2025. MeiraGTx secured $50 million in funding, including a $30 million equity investment from Sanofi, enhancing its financial stability for future developments. With multiple regulatory filings expected annually through 2027, MeiraGTx's diverse pipeline offers significant potential for long-term investor gains. Looking for a portfolio of ideas like this one? Members of Biotech Analysis Central get exclusive access to our subscriber-only portfolios. Learn More » alvarez/E+ via Getty Images The last time I wrote an article on MeiraGTx Holdings plc NASDAQ: MGTX ) it was with a Seeking Alpha article entitled “ MeiraGTx: Bota-
Show less
Read more
Impact Snapshot
Event Time:
MGTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MGTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MGTX alerts
High impacting MeiraGTx Holdings plc - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
MGTX
News
- MeiraGTx's Parkinson's gene therapy shows promise in Phase I/II study [Yahoo! Finance]Yahoo! Finance
- MGTX Stock Up on Upbeat Efficacy Data From Parkinson's Disease Study [Yahoo! Finance]Yahoo! Finance
- MeiraGTx Announces Positive Data from Randomized, Sham-controlled Clinical Bridging Study of AAV-GAD for the Treatment of Parkinson’s DiseaseGlobeNewswire
- Cell and Gene Therapy in Parkinson's Disease Clinical Trial Pipeline Analysis Demonstrates 18+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsight [Yahoo! Finance]Yahoo! Finance
- MeiraGTx Announces Poster Presentation on a Potential Treatment for MC4R Genetic Deficiency at the 2024 Society for Neuroscience ConferenceGlobeNewswire
MGTX
Earnings
- 8/12/24 - Miss
MGTX
Sec Filings
- 10/15/24 - Form 8-K
- 8/14/24 - Form SC
- 8/14/24 - Form 4
- MGTX's page on the SEC website